Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602433 · ClinicalTrials.gov registry record
Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 10
- Enrollment target
NCT00602433: Completed study, sponsored by Northwestern University.
NCT00602433 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00602433 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels. This clinical trial is looking at hormone changes in women with stage IIIB or stage IV non-small cell lung cancer receiving erlotinib.
Primary Outcome
We will determine if hyperandrogenemia is present in women with nonsmall cell lung cancer who are taking erlotinib.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-08 |
What the finished NCT00602433 record still lists
NCT00602433 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00602433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00602433 about?
NCT00602433 is a clinical study titled "Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib". Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels. This clinical trial is looking at hormone changes in women with stage IIIB or stage IV non-small cell lung cancer receiving erlotinib.
What is the current status of trial NCT00602433?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2007-12. Estimated completion is 2009-08.
Who is sponsoring clinical trial NCT00602433?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia